Top Page
Centrica
(LSE:CNA)
Centrica (CNA) vs. iShares MSCI United Kingdom ETF (EWC)
Centrica Business Overview & Revenue Model
Centrica Financial Statement Overview
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 19.49B | 19.91B | 26.46B | 23.74B | 14.74B |
| Gross Profit | 7.54B | 4.09B | -1.70B | 9.75B | 1.41B |
| EBITDA | 5.53B | 2.42B | 7.30B | 410.00M | 721.00M |
| Net Income | -72.00M | 1.33B | 3.93B | -782.00M | 586.00M |
Balance Sheet | |||||
| Total Assets | 15.41B | 18.73B | 21.37B | 29.04B | 27.09B |
| Cash, Cash Equivalents and Short-Term Investments | 4.31B | 6.22B | 6.85B | 4.84B | 5.06B |
| Total Debt | 3.05B | 3.51B | 4.10B | 3.96B | 4.58B |
| Total Liabilities | 11.92B | 13.92B | 17.13B | 27.76B | 24.34B |
| Stockholders Equity | 3.08B | 4.42B | 3.88B | 1.02B | 2.37B |
Cash Flow | |||||
| Free Cash Flow | 322.00M | 733.00M | 2.42B | 943.00M | 1.19B |
| Operating Cash Flow | 876.00M | 1.15B | 2.75B | 1.31B | 1.61B |
| Investing Cash Flow | -1.05B | 493.00M | 115.00M | -566.00M | 2.26B |
| Financing Cash Flow | -1.22B | -1.55B | -1.41B | -917.00M | -938.00M |
Centrica Technical Analysis
Centrica Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | £61.30B | 21.31 | 7.87% | 4.15% | -9.52% | 35.74% | |
74 Outperform | £31.01B | 16.49 | 7.09% | 2.98% | 1.78% | -50.72% | |
69 Neutral | £2.96B | 0.40 | 3.94% | 2.78% | -19.04% | -34.52% | |
66 Neutral | $17.65B | 18.10 | 5.60% | 3.62% | 6.62% | 11.55% | |
63 Neutral | £1.04B | 21.07 | 27.40% | 7.01% | 1.71% | -12.49% | |
59 Neutral | £9.17B | -112.68 | 1.68% | 2.86% | -4.82% | -123.58% | |
58 Neutral | £21.32M | -1.11 | -68.06% | ― | -60.76% | -230.39% |
Centrica Corporate Events
Centrica has disclosed that executive directors Christopher O’Shea and Russell O’Brien each acquired ordinary shares under the company’s Share Incentive Plan, administered by Equiniti. The transactions, involving small purchases of partnership and matching shares at around £1.98 per share on 10 March 2026, underline ongoing alignment between senior management and shareholders through equity-based remuneration, though the amounts are not large enough to materially affect the company’s capital structure.
Both sets of transactions were notified in accordance with Market Abuse Regulation requirements, reflecting Centrica’s adherence to regulatory standards on director dealings and transparency. For investors, the moves mainly serve as a routine signal of continued participation by top executives in the firm’s employee share schemes, rather than indicating any significant strategic or financial shift at the utilities group.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £218.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica has reported that, as of 28 February 2026, its issued share capital totals 5,064,902,964 ordinary shares, of which 459,860,617 are held in treasury. This leaves 4,605,042,347 shares in circulation carrying one vote each, a key reference figure for investors and other stakeholders when calculating disclosure thresholds and monitoring changes in significant shareholdings under UK transparency rules.
The most recent analyst rating on (GB:CNA) stock is a Hold with a £210.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica has disclosed that non-executive directors Frank Mastiaux and Sue Whalley have acquired ordinary shares in the company under their existing share purchase agreements. The transactions, executed on 25 February 2026 on the London Stock Exchange, modestly increase board members’ direct equity interests and align their incentives more closely with those of shareholders.
Mastiaux purchased 7,544 shares at £1.9014 per share, for a total consideration of £14,344.16, under an agreement dated 21 February 2026. Whalley acquired 513 shares at the same price, totalling £975.42, pursuant to an agreement signed on 8 September 2025, reinforcing governance practices that encourage director share ownership and signal continued board confidence in Centrica’s prospects.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £232.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica has published its 2025 Annual Report for the year ended 31 December 2025 on its website and submitted the document to the UK Financial Conduct Authority’s National Storage Mechanism for public inspection. The report contains the full regulated information required under UK disclosure rules, complementing the condensed financial statements and key 2025 events already released in the company’s preliminary results earlier the same day.
By making the full annual report and accounts available through both its own website and the FCA’s platform, Centrica reinforces its regulatory compliance and transparency for investors and other stakeholders. The coordinated release with preliminary results provides the market with detailed financial and operational disclosure for 2025, supporting informed analysis of the company’s performance and outlook within the UK energy sector.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica has announced that Non-Executive Director Carol Arrowsmith, who also chairs the Remuneration Committee, will step down from the board at the conclusion of the company’s 2026 AGM on 7 May, after nearly six years of service. The board has named current director Sue Whalley as the incoming Chair of the Remuneration Committee and a new member of the Nominations Committee, reinforcing continuity in Centrica’s governance and pay oversight structures.
Chair Kevin O’Byrne praised Arrowsmith’s contribution, highlighting her governance expertise and leadership in shaping the company’s remuneration framework over her tenure. The planned transition signals an orderly refresh of Centrica’s board leadership while maintaining focus on rigorous governance in executive pay and nominations, with no additional disclosures required under UK listing rules.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica has published its preliminary results for the year ended 31 December 2025 and made the full report available via its website and the UK financial regulator’s National Storage Mechanism. The company will present these 2025 preliminary results to analysts and institutional investors via a live webcast on 19 February 2026.
The board is proposing a final dividend of 3.67p per share, taking the total payout for 2025 to 5.5p per share, up from 4.5p in 2024. Subject to approval at the AGM on 7 May 2026, the final dividend will be paid on 14 May 2026 to shareholders on the register as of 10 April 2026, underlining the group’s confidence in its capital position and commitment to shareholder returns.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica has disclosed that executive directors Christopher O’Shea and Russell O’Brien have each acquired ordinary shares in the company through its Share Incentive Plan. The purchases, administered by Equiniti Share Plan Trustees, involved a combination of partnership and matching shares, reinforcing the alignment of senior management’s interests with those of shareholders.
The transactions, carried out on 10 February 2026 with trades on and off the London Stock Exchange, totalled 101 shares for each director at an average price of about £1.90 per share. While small in monetary value, these routine acquisitions highlight ongoing participation of top executives in Centrica’s employee share schemes, underlining governance transparency and long-term incentive structures for leadership.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica has completed the sale of its non-core European energy solutions businesses in Italy, the Netherlands and Hungary, as well as its Panoramic Power unit, generating proceeds of more than £80 million. The Italian and Dutch operations have been sold to Joulz, a 3i Infrastructure portfolio company, while the Hungarian business was divested via a management buyout, marking a further step in Centrica’s ongoing portfolio streamlining.
Chief executive Chris O’Shea said the disposals are intended to sharpen the focus of Centrica Business on core growth and innovation priorities, improving its ability to pursue new opportunities in key markets. The move follows recent asset sales at Spirit Energy and underscores Centrica’s strategy of recycling capital from non-core assets into new investments across the group, including large-scale, long-term infrastructure such as Sizewell C and the Grain LNG terminal, with implications for a more infrastructure-oriented earnings mix and capital allocation profile.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has confirmed that as of 31 January 2026 its issued share capital totals 5,064,902,964 ordinary shares, of which 460,040,495 are held in treasury. This leaves 4,604,862,469 shares in circulation carrying one vote per share, a figure the company highlights as the key denominator for shareholders and other obligated parties when calculating whether they must disclose holdings or changes in their interests under UK transparency rules.
The most recent analyst rating on (GB:CNA) stock is a Hold with a £206.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica has disclosed that non-executive directors Philippe Boisseau and Sue Whalley have acquired ordinary shares in the company through pre-agreed Share Purchase Agreements executed via Equiniti Financial Services. On 26 January 2026, Boisseau bought 1,021 shares and Whalley purchased 530 shares at a price of £1.841730 per share on the London Stock Exchange, signalling incremental director alignment with shareholder interests under the company’s standard governance and remuneration arrangements.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £2.18 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica has disclosed that executive directors Christopher O’Shea and Russell O’Brien have each acquired ordinary shares under the company’s Share Incentive Plan, in line with regulatory requirements for reporting transactions by persons discharging managerial responsibilities. The acquisitions, comprising both partnership and matching shares administered by Equiniti Share Plan Trustees, are relatively small in value but underscore ongoing alignment between senior management and shareholders, and reflect the routine operation of Centrica’s employee share ownership arrangements.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £2.18 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica has completed the £500 million extension of its share buyback programme, part of a wider capital return initiative launched in November 2022 that has seen the company repurchase about £2.0 billion of its ordinary shares, equivalent to roughly 25% of its then-issued share capital. The company disclosed that on 12 January 2026 it bought 84,365 shares at an average price of 180.8081 pence through J.P. Morgan Securities, taking total purchases since September 2025 to 147,027,443 shares and leaving 460,124,571 shares held in treasury out of 4,604,778,393 shares in issue (excluding treasury), underscoring an ongoing focus on capital allocation and shareholder returns.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £2.18 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has continued executing the second tranche of its share buyback programme, repurchasing 201,235 ordinary shares on 9 January 2026 at a volume-weighted average price of 178.9655 pence per share via J.P. Morgan Securities. Since the start of this tranche in September 2025, the company has bought back 146.9 million shares for approximately £249.8 million (excluding costs), and now holds 460 million shares in treasury, leaving about 4.6 billion shares in issue, a move that effectively reduces the free float and can enhance earnings per share and capital returns for remaining shareholders.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £2.18 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica has continued executing the second tranche of its share buyback programme, repurchasing 1,058,825 ordinary shares on 9 January 2026 at a volume-weighted average price of 180.4105 pence per share via J.P. Morgan Securities, with the shares to be held in treasury. Since the buyback was launched in September 2025, the group has acquired 147.8 million shares for just over £251 million, leaving 460.9 million shares in treasury and 4.60 billion shares in issue, underlining an ongoing capital return to investors and a tighter free float that may support earnings per share over time.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £2.18 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has continued executing the second tranche of its share buyback programme, repurchasing 1,098,671 ordinary shares on 8 January 2026 at a volume-weighted average price of 176.5799 pence per share via J.P. Morgan Securities, with the shares to be held in treasury. Since the programme’s launch on 22 September 2025, the company has acquired a total of 146,741,843 shares for approximately £249.5 million, lifting its treasury holdings to 459,841,213 shares and leaving 4,605,061,751 shares in issue, a move that tightens the free float and underscores Centrica’s ongoing capital return strategy for shareholders.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £203.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica has continued the second tranche of its share buyback programme by repurchasing 1,088,950 ordinary shares on 7 January 2026 at a volume-weighted average price of 176.5194 pence per share, with the shares to be held in treasury. Since launching this phase of the programme in September 2025, the company has bought back 145.6 million shares for approximately £247.5 million, bringing its total treasury holding to about 458.7 million shares and leaving 4.61 billion shares in issue, a capital structure move that can support earnings per share and signal management’s confidence to investors.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £203.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has continued the second tranche of its share buyback programme, repurchasing 1,097,563 ordinary shares on 6 January 2026 at a volume-weighted average price of 175.4889 pence per share through J.P. Morgan Securities, with the shares to be held in treasury. Since the start of this tranche on 22 September 2025, the company has bought back 144,554,222 shares at a cost of about £245.6m, leaving it with 457,653,592 shares held in treasury and 4,607,249,372 shares in issue, underlining an ongoing capital return to shareholders and tighter management of its equity base.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £203.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has continued execution of its share buyback programme, repurchasing 1,121,853 ordinary shares on 5 January 2026 at a volume-weighted average price of 172.9334 pence per share through J.P. Morgan Securities, with the shares to be held in treasury. Since the launch of this second tranche of the buyback in September 2025, the company has acquired 143,456,659 shares for approximately £243.7 million, bringing its treasury holdings to 456,556,029 shares and reducing the free float to 4,608,346,935 shares in issue, a move that signals continued capital returns to shareholders and may support earnings per share by shrinking the equity base.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £203.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica has continued execution of the second tranche of its share buyback programme, repurchasing 1,120,369 ordinary shares on 2 January 2026 at a volume-weighted average price of 173.33 pence per share via J.P. Morgan Securities, with the shares to be held in treasury. Since the programme began in September 2025, the group has bought back more than 142 million shares for around £241.8 million, lifting treasury holdings to roughly 455 million shares and reducing the free float to about 4.61 billion shares, a move that tightens the share count and may enhance earnings per share and capital returns for remaining investors.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £203.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica has reported that, as of 31 December 2025, its issued share capital totalled 5,064,902,964 ordinary shares, of which 454,315,003 are held in treasury, leaving 4,610,587,961 shares in circulation with full voting rights. The company confirmed that this voting share figure should be used by investors and other obligated parties as the denominator when calculating whether they need to disclose holdings or changes in their interests under UK transparency regulations, ensuring clarity on ownership thresholds and regulatory compliance for shareholders.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £203.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica has continued executing the second tranche of its share buyback programme, repurchasing 1,140,716 ordinary shares on 31 December 2025 at an average price of 170.2163 pence per share via J.P. Morgan Securities, with the shares to be held in treasury. Since the buyback’s launch in September 2025, the company has acquired 141,214,437 shares for approximately £239.8 million, taking its treasury holding to 454.3 million shares and leaving 4.61 billion shares in issue, underscoring an ongoing capital return strategy that reduces the free float and can enhance earnings per share for remaining shareholders.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £203.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has continued its ongoing share buyback programme, purchasing 1,136,420 ordinary shares on 30 December 2025 at a volume-weighted average price of 169.8045 pence per share through J.P. Morgan Securities, with the shares to be held in treasury. Since the launch of the second tranche of the buyback in late September, the company has repurchased over 140 million shares at a cost of approximately £238 million, bringing its treasury holding to 453.2 million shares and leaving 4.61 billion shares in issue, signalling sustained capital returns to shareholders and active management of its equity base.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £203.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has continued executing the second tranche of its share buyback programme, repurchasing 1,154,459 ordinary shares on 29 December 2025 at an average price of 168.7104 pence per share through J.P. Morgan Securities, with the shares to be held in treasury. Since the buyback’s launch on 22 September 2025, the company has acquired 138,937,301 shares for approximately £235.9 million, leaving 4,612,865,097 shares in issue excluding 452,037,867 shares now held in treasury, underscoring management’s ongoing capital return to shareholders and its active management of the company’s equity base.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £203.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has cancelled 35,704,250 ordinary shares previously held in treasury, in line with its policy to keep treasury shares below 10% of total issued share capital. Following the cancellation, the company now holds 450,883,408 ordinary shares in treasury, representing 8.90% of its total issued share capital, with 4,614,019,556 voting rights remaining in issue, a move that modestly adjusts its capital structure and share base for investors.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £203.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica has disclosed that non-executive directors Philippe Boisseau and Sue Whalley have acquired additional ordinary shares in the company under previously agreed Share Purchase Agreements. The purchases, executed on 29 December 2025 on the London Stock Exchange at £1.6835 per share, involved 1,116 shares for Boisseau and 579 shares for Whalley, signalling continued board-level alignment with shareholder interests through increased personal equity stakes.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £203.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has continued executing the second tranche of its share buyback programme, repurchasing 1,156,316 ordinary shares on 24 December 2025 at an average price of 168.8752 pence per share via J.P. Morgan Securities, with the shares to be held in treasury. Since the start of this tranche in September, the company has bought back 137.8 million shares for nearly £234 million, bringing its treasury holding to about 486.6 million shares and reducing the free float to 4.61 billion shares, underscoring an ongoing capital return strategy that may enhance earnings per share and support shareholder value.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £203.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica has continued the second tranche of its share buyback programme with the repurchase of 1,150,322 ordinary shares on 23 December 2025 at an average price of 168.8074 pence per share, with the stock to be held in treasury. Since the programme began on 22 September 2025, the company has bought back a total of 136,626,526 shares for approximately £232 million, leaving 4,615,175,872 shares in issue excluding 485,431,342 shares now held in treasury, underscoring management’s ongoing focus on returning capital to shareholders and actively managing the company’s capital structure.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £203.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica has continued to execute the second tranche of its share buyback programme, repurchasing 1,150,354 ordinary shares on 22 December 2025 at an average price of 167.8956 pence per share through J.P. Morgan Securities, with the shares to be held in treasury. Since the launch of this phase of the programme on 22 September 2025, the group has bought back more than 135 million shares for about £230.1 million, leaving 4.62 billion shares in issue (excluding 484.3 million held in treasury), a move that effectively concentrates earnings per share and signals ongoing balance sheet strength and commitment to shareholder returns.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £203.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica has continued executing the second tranche of its share buyback programme, repurchasing 1,127,771 ordinary shares on 19 December 2025 at a volume-weighted average price of 168.8858 pence per share through J.P. Morgan Securities, with the stock to be held in treasury. Since the programme’s launch on 22 September 2025, the company has bought back 134,325,850 shares for approximately £228.2 million, bringing its treasury holding to 483,138,586 shares and reducing the free float to 4,617,468,628 shares, a capital management move that can enhance earnings per share and signals continued confidence in its balance sheet to investors.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £203.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.